SE9802549D0 - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
SE9802549D0
SE9802549D0 SE9802549A SE9802549A SE9802549D0 SE 9802549 D0 SE9802549 D0 SE 9802549D0 SE 9802549 A SE9802549 A SE 9802549A SE 9802549 A SE9802549 A SE 9802549A SE 9802549 D0 SE9802549 D0 SE 9802549D0
Authority
SE
Sweden
Prior art keywords
fluoro
chloro
propyl
proviso
hydrogen
Prior art date
Application number
SE9802549A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9802549A priority Critical patent/SE9802549D0/xx
Publication of SE9802549D0 publication Critical patent/SE9802549D0/xx
Priority to JP2000560098A priority patent/JP4045070B2/ja
Priority to EP99933452A priority patent/EP1095021B1/en
Priority to APAP/P/2001/002041A priority patent/AP1366A/en
Priority to CZ20010094A priority patent/CZ300229B6/cs
Priority to PT99933452T priority patent/PT1095021E/pt
Priority to YUP-15/01A priority patent/RS50128B/sr
Priority to AT99933452T priority patent/ATE250036T1/de
Priority to KR10-2000-7014618A priority patent/KR100516382B1/ko
Priority to NZ508923A priority patent/NZ508923A/xx
Priority to AU49504/99A priority patent/AU751103B2/en
Priority to CNB998085987A priority patent/CN1157378C/zh
Priority to IDW20010331A priority patent/ID27423A/id
Priority to IL14034699A priority patent/IL140346A0/xx
Priority to TR2001/00087T priority patent/TR200100087T2/xx
Priority to RU2001104342/04A priority patent/RU2213733C2/ru
Priority to DE69911415T priority patent/DE69911415T2/de
Priority to DK99933452T priority patent/DK1095021T3/da
Priority to PCT/SE1999/001270 priority patent/WO2000003991A1/en
Priority to OA00100011A priority patent/OA11906A/en
Priority to EEP200100010A priority patent/EE04673B1/xx
Priority to BRPI9912109-3A priority patent/BR9912109B1/pt
Priority to PL345388A priority patent/PL199783B1/pl
Priority to CA002336968A priority patent/CA2336968C/en
Priority to MEP-2008-574A priority patent/ME00374B/me
Priority to UA2000127299A priority patent/UA64791C2/uk
Priority to HU0103224A priority patent/HU229427B1/hu
Priority to ES99933452T priority patent/ES2205854T3/es
Priority to IL140346A priority patent/IL140346A/en
Priority to IS5775A priority patent/IS2208B/is
Priority to ZA200007593A priority patent/ZA200007593B/xx
Priority to HR20010039A priority patent/HRP20010039B1/xx
Priority to NO20010211A priority patent/NO317601B1/no
Priority to HK01104765A priority patent/HK1035715A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9802549A 1998-07-15 1998-07-15 Quinoline derivatives SE9802549D0 (sv)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives
ES99933452T ES2205854T3 (es) 1998-07-15 1999-07-14 Derivados de quinolina.
DE69911415T DE69911415T2 (de) 1998-07-15 1999-07-14 Chinolinderivate
PCT/SE1999/001270 WO2000003991A1 (en) 1998-07-15 1999-07-14 Quinoline derivatives
APAP/P/2001/002041A AP1366A (en) 1998-07-15 1999-07-14 Quinoline derivatives.
DK99933452T DK1095021T3 (da) 1998-07-15 1999-07-14 Quinolinderivater
PT99933452T PT1095021E (pt) 1998-07-15 1999-07-14 Derivados de quinolina
YUP-15/01A RS50128B (sr) 1998-07-15 1999-07-14 Derivati hinolina
AT99933452T ATE250036T1 (de) 1998-07-15 1999-07-14 Chinolinderivate
EP99933452A EP1095021B1 (en) 1998-07-15 1999-07-14 Quinoline derivatives
NZ508923A NZ508923A (en) 1998-07-15 1999-07-14 N-phenyl-1-Methyl-2-oxo-quinoline-3-carboxamide derivatives, pharmaceuticals thereof and their use in therapy
AU49504/99A AU751103B2 (en) 1998-07-15 1999-07-14 Quinoline derivatives
CNB998085987A CN1157378C (zh) 1998-07-15 1999-07-14 喹啉衍生物
IDW20010331A ID27423A (id) 1998-07-15 1999-07-14 Turunan kuinolin
IL14034699A IL140346A0 (en) 1998-07-15 1999-07-14 Quinoline derivatives
OA00100011A OA11906A (en) 1998-07-15 1999-07-14 Quinoline derivatives.
RU2001104342/04A RU2213733C2 (ru) 1998-07-15 1999-07-14 Производные хинолина, способ их получения (варианты), фармацевтическая композиция и способ лечения с их использованием
JP2000560098A JP4045070B2 (ja) 1998-07-15 1999-07-14 キノリン誘導体
CZ20010094A CZ300229B6 (cs) 1998-07-15 1999-07-14 Deriváty chinolinu
KR10-2000-7014618A KR100516382B1 (ko) 1998-07-15 1999-07-14 퀴놀린 유도체
TR2001/00087T TR200100087T2 (tr) 1998-07-15 1999-07-14 Kinolin türevleri
EEP200100010A EE04673B1 (et) 1998-07-15 1999-07-14 Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
BRPI9912109-3A BR9912109B1 (pt) 1998-07-15 1999-07-14 compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.
PL345388A PL199783B1 (pl) 1998-07-15 1999-07-14 Związki pochodne chinolino-3-karboksyamidu, zawierające je kompozycje farmaceutyczne, sposób ich wytwarzania i ich zastosowanie
CA002336968A CA2336968C (en) 1998-07-15 1999-07-14 Quinoline derivatives
MEP-2008-574A ME00374B (me) 1998-07-15 1999-07-14 Derivati hinolina
UA2000127299A UA64791C2 (en) 1998-07-15 1999-07-14 Quinoline derivatives, a method for the preparation thereof, a pharmaceutical composition and a method for treatment of diseases resulting from pathological inflammation or autoimmunity
HU0103224A HU229427B1 (en) 1998-07-15 1999-07-14 Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
IL140346A IL140346A (en) 1998-07-15 2000-12-14 Quinoline derivatives, pharmaceutical preparations containing them and a process for their preparation
IS5775A IS2208B (is) 1998-07-15 2000-12-18 Quinoline afleiður
ZA200007593A ZA200007593B (en) 1998-07-15 2000-12-18 Quinoline Derivatives.
HR20010039A HRP20010039B1 (en) 1998-07-15 2001-01-12 Quinoline derivatives
NO20010211A NO317601B1 (no) 1998-07-15 2001-01-12 Kinolinderivater
HK01104765A HK1035715A1 (en) 1998-07-15 2001-07-10 Quinoline derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives

Publications (1)

Publication Number Publication Date
SE9802549D0 true SE9802549D0 (sv) 1998-07-15

Family

ID=20412093

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives

Country Status (33)

Country Link
EP (1) EP1095021B1 (uk)
JP (1) JP4045070B2 (uk)
KR (1) KR100516382B1 (uk)
CN (1) CN1157378C (uk)
AP (1) AP1366A (uk)
AT (1) ATE250036T1 (uk)
AU (1) AU751103B2 (uk)
BR (1) BR9912109B1 (uk)
CA (1) CA2336968C (uk)
CZ (1) CZ300229B6 (uk)
DE (1) DE69911415T2 (uk)
DK (1) DK1095021T3 (uk)
EE (1) EE04673B1 (uk)
ES (1) ES2205854T3 (uk)
HK (1) HK1035715A1 (uk)
HR (1) HRP20010039B1 (uk)
HU (1) HU229427B1 (uk)
ID (1) ID27423A (uk)
IL (2) IL140346A0 (uk)
IS (1) IS2208B (uk)
ME (1) ME00374B (uk)
NO (1) NO317601B1 (uk)
NZ (1) NZ508923A (uk)
OA (1) OA11906A (uk)
PL (1) PL199783B1 (uk)
PT (1) PT1095021E (uk)
RS (1) RS50128B (uk)
RU (1) RU2213733C2 (uk)
SE (1) SE9802549D0 (uk)
TR (1) TR200100087T2 (uk)
UA (1) UA64791C2 (uk)
WO (1) WO2000003991A1 (uk)
ZA (1) ZA200007593B (uk)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390148C (zh) * 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
CA2487891A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
CN100490793C (zh) * 2002-06-11 2009-05-27 株式会社医药分子设计研究所 神经变性疾病治疗药
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
JP5832716B2 (ja) 2005-10-19 2015-12-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶，及びその製造方法
SI2035001T1 (sl) 2006-06-12 2012-03-30 Teva Pharma Stabilni pripravki lakvinimoda
WO2008113006A1 (en) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
NZ591315A (en) 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
AU2010276748A1 (en) 2009-07-30 2012-03-15 Teva Pharmaceutical Industries Ltd. Treatment of Crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
CN102781240A (zh) 2010-03-03 2012-11-14 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CA2809287C (en) * 2010-08-27 2018-05-22 Gruenenthal Gmbh Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
MX2013004169A (es) 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
EA201491460A1 (ru) 2012-02-03 2015-01-30 Тева Фармасьютикал Индастриз Лтд. ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
WO2013123419A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
JP5868839B2 (ja) 2012-12-27 2016-02-24 三菱重工業株式会社 チャー払出管
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN105367492B (zh) * 2014-08-28 2018-07-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
CN107108510B (zh) 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
CN107072989B (zh) 2014-11-19 2020-07-03 活跃生物技术有限公司 用于治疗白血病的喹啉甲酰胺
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) * 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
KR20220149579A (ko) 2020-03-03 2022-11-08 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
MX2023000903A (es) 2020-07-23 2023-04-20 Univ Erasmus Med Ct Rotterdam Proteinas s100 como nuevos objetivos terapeuticos en neoplasias mieloproliferativas.
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
CN117295492A (zh) 2021-05-25 2023-12-26 活跃生物技术有限公司 多个他喹莫德粒子及其用途
EP4363404A1 (en) 2021-07-02 2024-05-08 Active Biotech AB A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
JPH07224040A (ja) * 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
HUP0103224A3 (en) 2002-11-28
DE69911415D1 (de) 2003-10-23
OA11906A (en) 2006-04-10
AP1366A (en) 2005-01-26
HUP0103224A2 (hu) 2002-01-28
ATE250036T1 (de) 2003-10-15
IL140346A0 (en) 2002-02-10
DK1095021T3 (da) 2003-11-24
DE69911415T2 (de) 2004-07-08
TR200100087T2 (tr) 2001-06-21
HRP20010039B1 (en) 2009-04-30
KR20010053115A (ko) 2001-06-25
WO2000003991A1 (en) 2000-01-27
KR100516382B1 (ko) 2005-09-26
CZ300229B6 (cs) 2009-03-25
EP1095021B1 (en) 2003-09-17
UA64791C2 (en) 2004-03-15
RS50128B (sr) 2009-03-25
NO317601B1 (no) 2004-11-22
ID27423A (id) 2001-04-05
PL199783B1 (pl) 2008-10-31
JP2002520395A (ja) 2002-07-09
HU229427B1 (en) 2013-12-30
NO20010211L (no) 2001-03-15
ES2205854T3 (es) 2004-05-01
IL140346A (en) 2006-07-05
IS2208B (is) 2007-02-15
PL345388A1 (en) 2001-12-17
RU2213733C2 (ru) 2003-10-10
AU751103B2 (en) 2002-08-08
BR9912109B1 (pt) 2012-08-21
NZ508923A (en) 2002-09-27
HK1035715A1 (en) 2001-12-07
AP2001002041A0 (en) 2001-03-31
MEP57408A (en) 2011-05-10
BR9912109A (pt) 2001-05-02
EP1095021A1 (en) 2001-05-02
CZ200194A3 (en) 2001-05-16
ZA200007593B (en) 2001-07-09
HRP20010039A2 (en) 2001-12-31
EE200100010A (et) 2002-06-17
PT1095021E (pt) 2003-12-31
CA2336968A1 (en) 2000-01-27
IS5775A (is) 2000-12-18
YU1501A (sh) 2003-10-31
NO20010211D0 (no) 2001-01-12
AU4950499A (en) 2000-02-07
CN1157378C (zh) 2004-07-14
ME00374B (me) 2011-05-10
JP4045070B2 (ja) 2008-02-13
CA2336968C (en) 2005-08-30
EE04673B1 (et) 2006-08-15
CN1309641A (zh) 2001-08-22

Similar Documents

Publication Publication Date Title
SE9802549D0 (sv) Quinoline derivatives
SE9801474D0 (sv) Quinoline Derivatives
AP1425A (en) Quinoline derivatives.
TR200000837A2 (tr) Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler.
ATE37179T1 (de) Dihydropyridazinone.
ATE247654T1 (de) Neue heterozyklische verbindungen
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
CA2205274A1 (en) Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones
BR0213731A (pt) Compostos de silìcio
ES8605507A1 (es) Un compuesto de 3-indolcarboxamida
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
DE69526452D1 (de) Indolditerpen alkaloide
EA200101050A1 (ru) Замещенные бензолактамные соединения
MXPA04000615A (es) Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
SE0401578D0 (sv) Novel compounds
IT1205640B (it) Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
ATE56442T1 (de) 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
SE0400440D0 (sv) Novel Cinnamic Amides
DK0660840T3 (da) Phosphono-substituerede tetrazolderivater.
ATE264320T1 (de) 5-aminoalkyl- und 5-aminocarbonylsubstituierte indole
MX9601953A (es) Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona.
MX9705144A (es) Uso de un compuesto de carboestirilo para preparar un inhibidor de la produccion o secrecion del factor de necrosis tumoral alfa.